Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synergetics extends Stryker deal, ends suit

This article was originally published in Clinica

Executive Summary

O'Fallon, Missouri-based Synergetics USA has extended its exclusive worldwide agreement with Stryker for the distribution of its radiofrequency generator for the percutaneous treatment of pain. The original five-year agreement was due to end December 31 2009 but has now been prolonged by an extra year. The contract renewal also includes an increased minimum purchase obligation for each remaining year. The Stryker collaboration provided Synergetics with about $2m in sales for the nine months ended April 30 2007, approximately 6% of total sales for the period. Separately, Synergetics has announced that a US court has dismissed two former employees' claim to vacate a post-judgement motion made in favour of the company relating to allegations that they interfered in the company's business relationships (see Clinica No 1175, p 16). However, the court agreed with Charles Hurst and Michael McGowan's claims that Synergetics had engaged in "improper pre-trial conduct", and awarded them $1.17m in sanctions, which Synergetics will draw out of the original damages of $2.35m.

You may also be interested in...



Covid-19 Scam Complaints Double In A Week, But FTC Enforcement Considers 'Good Faith' Factor

FTC pursuing bogus health and other products or services capitalizing on Covid-19 fear with scams skyrocketing. However, FTC says its enforcement will consider whether businesses are making good faith efforts to produce products in high demand.

No Facility Inspections? No Shortage Of Bogus Pandemic Claims Found Online By US Agencies

Warning letters show FDA's coronavirus investigations inthe consumer health marketplace didn't stop when it suspended facility inspections. The letters identify firms that previously marketed only bedding products as offering supplements with coronavirus claims or that are in other countries and are shipping to US consumers products promoted with coronavirus claims.

COVID-19, Lockdown Affect Trials in India But Coping Efforts In Hand

The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.

Topics

UsernamePublicRestriction

Register

MT049574

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel